Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Tongluo Xiezhuo prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by Dongzhimen Hospital at the Beijing University of Chinese Medicine. It is primarily indicated for the treatment of chronic renal failure (CRF) and chronic kidney disease (CKD), specifically for patients presenting with the TCM syndrome pattern of Qi deficiency, blood stasis, and damp-heat. The formula's therapeutic strategy is based on tonifying Qi (Yiqi), dredging the collaterals to improve microcirculation (Tongluo), and eliminating metabolic "turbidity" or toxins (Xiezhuo). In clinical research, it is typically evaluated as an add-on therapy to standard Western medical treatments to delay the progression of renal dysfunction and improve clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi tongluo xiezhuo prescription.